SALT LAKE CITY, UT / ACCESSWIRE / June 22, 2015 / While several key factors contribute to the success of any great brand, such as a quality product line, inventive advertising, and an experienced leadership team, few companies within this sector achieve widespread success without a growing presence in global markets. Rejuvel Bio-Sciences, Inc. (OTCQB: NUUU), which trades at .59 per share , has recently taken several steps to shore up its global brand appeal, strengthening the foundation of an up-and-coming brand ready to break through as a household name.
Rejuvel Bio-Sciences, Inc.'s flagship product is its REJUVEL 3D Microgravity Cell Renewal Cream, a state-of-the-art facial cream that uses bioreactor technology licensed from NASA. REJUVEL 3D burst onto the scene earlier in 2015 when it was included in the Academy Awards "swag bag," and continued its dominance of Hollywood when it was recently featured in Mother's Day celebrity gift boxes that found their way into the hands of some of the biggest stars in the world including Eva Mendes, Alicia Keys, and Kate Hudson.
Last month the company received its CPNP Reference Number so that it can begin product distribution in the European Union and its member states. This will not only allow REJUVEL 3D to be sold in Europe, but the company's agreement also included directives allowing Rejuvel to take full advantage of home shopping television programming for its products.
Building on the backbone of both this development and a unique, proprietary product, Rejuvel Bio-Sciences recently broadened its scope by entering into a distribution agreement with RJVL Ltd, based in the Ukraine, the largest country within Europe. Rejuvel' Vice-President, John Stickler, indicated: "Ukraine has a population of 45 million people and presents an incredible opportunity for us because they are familiar with NASA's scientific accomplishments."
In addition to the company's progress in international markets, a closer look at a few stocks within personal care industries reveals a particularly promising outlook. A 9% drop in the first quarter for Elizabeth Arden (NASDAQ: RDEN) is revealing of a recent trend among cosmetics consumers to buck traditional product lines and marketing for cosmetics that offer an entirely new experience, such as Rejuvel's age-defying, NASA-licensed cream.
Another such product is Revita, offered by DS Healthcare (DSKX) trading at 4.51. Revita is a hair regrowth treatment utilizing a completely new approach that targets multiple underlying hair loss triggers. The product is also known for its lack of scalp and skin irritation, and social media endorsements have helped DSKX see a significant spike in recent months.
LifeVantage Corporation (LFVN), which takes an advanced, rounded approach to anti-aging and transformative health. The company makes and markets Protandim and Nrf2 Synergizer, two dietary supplements used to complement external sports-based health regiments created and studied by the company. By investigating all facets of health and wellness while supplementing exercise regiments with its skin care regiments an other health products, LifeVantage capitalizes on several untapped aspects of the personal care market.
The new wave of cosmetics and personal care companies like NUUU and LFVN stand poised to supplant some of the larger players incapable of adapting to advances in research, science, and marketing. With its celebrity associations and a fast track on the international market, NUUU in particular stands apart from the crowd, offering investors a company whose global interests make it primed for possible success.
Seraphim Strategies is a third party publisher. Not a registered broker/dealer/analyst/adviser, holds no investment licenses and may not sell, offer to sell or offer to buy any security. Market updates, news alerts and corporate profiles are not a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is not to be interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. For full disclaimer please read http://tomorrowsbluechips.com/disclaimer/ This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may," "future," "plan" or "planned," "will" or "should," "expected," "anticipates," "draft," "eventually," or "projected." You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements.
SOURCE: Seraphim Strategies LLC